Lancet Neurology

(The TQCC of Lancet Neurology is 61. The table below lists those papers that are above that threshold based on CrossRef citation counts. The publications cover those that have been published in the past four years, i.e., from 2019-03-01 to 2023-03-01.)
Global, regional, and national burden of neurological disorders, 1990–2016: a systematic analysis for the Global Burden of Disease Study 20161639
Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis1595
Global, regional, and national burden of stroke, 1990–2016: a systematic analysis for the Global Burden of Disease Study 20161403
Global, regional, and national burden of Alzheimer's disease and other dementias, 1990–2016: a systematic analysis for the Global Burden of Disease Study 20161105
Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies918
Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study842
Global, regional, and national burden of stroke and its risk factors, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019776
Global, regional, and national burden of traumatic brain injury and spinal cord injury, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016687
Stroke in China: advances and challenges in epidemiology, prevention, and management593
Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria586
Small vessel disease: mechanisms and clinical implications561
Global, regional, and national burden of multiple sclerosis 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016526
Genetic risk factors for ischaemic stroke and its subtypes (the METASTROKE Collaboration): a meta-analysis of genome-wide association studies369
Global, regional, and national burden of epilepsy, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016368
An update on anti-NMDA receptor encephalitis for neurologists and psychiatrists: mechanisms and models341
The global burden of stroke: persistent and disabling302
Global brain inflammation in stroke291
Association between circadian rhythms and neurodegenerative diseases262
Global, regional, and national burden of brain and other CNS cancer, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016261
CSF and blood biomarkers for Parkinson's disease249
Frontotemporal dementia and its subtypes: a genome-wide association study243
Gait impairments in Parkinson's disease236
Spreading depolarisations and outcome after traumatic brain injury: a prospective observational study213
Retinal thickness measured with optical coherence tomography and risk of disability worsening in multiple sclerosis: a cohort study212
Incidence and prevalence of dementia associated with transient ischaemic attack and stroke: analysis of the population-based Oxford Vascular Study208
Penumbral imaging and functional outcome in patients with anterior circulation ischaemic stroke treated with endovascular thrombectomy versus medical therapy: a meta-analysis of individual patient-lev208
Integration of genetic risk factors into a clinical algorithm for multiple sclerosis susceptibility: a weighted genetic risk score204
Effectiveness of home-based and remotely supervised aerobic exercise in Parkinson's disease: a double-blind, randomised controlled trial196
Case-mix, care pathways, and outcomes in patients with traumatic brain injury in CENTER-TBI: a European prospective, multicentre, longitudinal, cohort study195
Untreated clinical course of cerebral cavernous malformations: a prospective, population-based cohort study191
Implications of sleep disturbance and inflammation for Alzheimer's disease dementia176
Imaging biomarkers of vulnerable carotid plaques for stroke risk prediction and their potential clinical implications176
Detection, risk factors, and functional consequences of cerebral microinfarcts174
Migraine and the trigeminovascular system—40 years and counting173
Traumatic brain injury in China172
The role of astroglia in Alzheimer's disease: pathophysiology and clinical implications161
Blood pressure variability and outcome after acute intracerebral haemorrhage: a post-hoc analysis of INTERACT2, a randomised controlled trial161
Investigation of frailty as a moderator of the relationship between neuropathology and dementia in Alzheimer's disease: a cross-sectional analysis of data from the Rush Memory and Aging Project159
An exoskeleton controlled by an epidural wireless brain–machine interface in a tetraplegic patient: a proof-of-concept demonstration159
Blantyre Malaria Project Epilepsy Study (BMPES) of neurological outcomes in retinopathy-positive paediatric cerebral malaria survivors: a prospective cohort study154
Immune dysregulation in amyotrophic lateral sclerosis: mechanisms and emerging therapies139
Associations between blood pressure across adulthood and late-life brain structure and pathology in the neuroscience substudy of the 1946 British birth cohort (Insight 46): an epidemiological study137
Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial133
Therapeutic interventions in patients with prolonged disorders of consciousness131
Timing of anticoagulation after recent ischaemic stroke in patients with atrial fibrillation124
Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial123
Deferoxamine mesylate in patients with intracerebral haemorrhage (i-DEF): a multicentre, randomised, placebo-controlled, double-blind phase 2 trial121
Association between pathological and MRI findings in multiple sclerosis115
Global burden of traumatic brain and spinal cord injury114
Hereditary spastic paraplegia: from diagnosis to emerging therapeutic approaches112
Association between plasma GFAP concentrations and MRI abnormalities in patients with CT-negative traumatic brain injury in the TRACK-TBI cohort: a prospective multicentre study110
Magnetic resonance spectroscopy assessment of brain injury after moderate hypothermia in neonatal encephalopathy: a prospective multicentre cohort study109
Blood pressure control and clinical outcomes in acute intracerebral haemorrhage: a preplanned pooled analysis of individual participant data108
Clinical challenges and future therapeutic approaches for neuronal ceroid lipofuscinosis108
Cerebral microbleeds and stroke risk after ischaemic stroke or transient ischaemic attack: a pooled analysis of individual patient data from cohort studies106
Pathophysiology, prevention, and treatment of medication overuse headache102
Clinical presentation, diagnosis, and management of fetal alcohol spectrum disorder101
Dual antiplatelet therapy using cilostazol for secondary prevention in patients with high-risk ischaemic stroke in Japan: a multicentre, open-label, randomised controlled trial100
Progress in diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy98
Serum neurofilament light chain in genetic frontotemporal dementia: a longitudinal, multicentre cohort study98
Long-term effect of thymectomy plus prednisone versus prednisone alone in patients with non-thymomatous myasthenia gravis: 2-year extension of the MGTX randomised trial97
Stroke genetics: discovery, biology, and clinical applications90
Safety, efficacy, and mechanisms of action of cannabinoids in neurological disorders86
Self-managed, computerised speech and language therapy for patients with chronic aphasia post-stroke compared with usual care or attention control (Big CACTUS): a multicentre, single-blinded, randomis86
The genetic basis of DOORS syndrome: an exome-sequencing study86
Safety of the tau-directed monoclonal antibody BIIB092 in progressive supranuclear palsy: a randomised, placebo-controlled, multiple ascending dose phase 1b trial85
Parkinson's disease in the Western Pacific Region84
Spinal cord involvement in multiple sclerosis and neuromyelitis optica spectrum disorders84
MRI in traumatic spinal cord injury: from clinical assessment to neuroimaging biomarkers79
Safety and efficacy of deferiprone for pantothenate kinase-associated neurodegeneration: a randomised, double-blind, controlled trial and an open-label extension study79
Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial77
Effectiveness and cost-effectiveness of interferon beta and glatiramer acetate in the UK Multiple Sclerosis Risk Sharing Scheme at 6 years: a clinical cohort study with natural history comparator75
Priorities to reduce the burden of stroke in Latin American countries75
Safety and efficacy of intravenous bimagrumab in inclusion body myositis (RESILIENT): a randomised, double-blind, placebo-controlled phase 2b trial73
Early highly effective versus escalation treatment approaches in relapsing multiple sclerosis69
Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 trial66
The global burden of neurological disorders65
Long-term outcomes of stenting and endarterectomy for symptomatic carotid stenosis: a preplanned pooled analysis of individual patient data65
Diagnosis, prognosis, and treatment of leukodystrophies64
Management of epilepsy in women61